Supported by an unrestricted educational grant from Medtronic

An 89-year-old male with hypertension, dyslipidemia, current smoking, stage III kidney disease, and a history of diagonal PCI in 2010 presented with severe symptomatic aortic stenosis and a small annulus (410 mm²), with RBBB on ECG.

Via bilateral femoral access,...

This session delves into the role of mitral transcatheter edge-to-edge repair (TEER) in advanced heart failure patients. Understand the indications for mitral TEER in severe left ventricular dysfunction, prognostic challenges in heart failure with severe mitral regurgitation, and review therapeutic alternatives including the pathway from TEER...

This session focuses on the challenges and strategies of redo TAVI, from careful planning to valve selection and tailored procedural approaches. Learn how to manage different valve platforms, optimise outcomes in valve-in-valve scenarios, and prevent complications such as coronary obstruction through real case discussions.

In this interview, Chiara De Biase and Jean Marco embark on a journey through the history of interventional medicine, focusing on Charles Dotter, the pioneer of transluminal angioplasty, and Andreas Grüntzig.

In this first episode, they discuss Dotter's groundbreaking contributions, including the first interventional transluminal angioplasty in 1964, which revolutionized...

The novel sirolimus-eluting ultra-high molecular weight APTITUDE bioreabsorbable vascular scaffold (BRS) displays higher mechanical strength, expansion capabilities and resistance to fracture compared to other BRS technologies. RENASCENT II is a prospective, multicentre first-in-human clinical study evaluating the clinical performance of the APTITUDE BRS in the treatment...

This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...